Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged

investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat

Agios Pharmaceuticals stock shed about half its value Wednesday after the company's sickle cell disease treatment lagged expectations.
The post Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-11-19 17:34:25.
The Entire Business World on a Single Page. Free to Use →